Your Directors have pleasure in presenting the 55^th
Annual Report along with the Audited Accounts for the
financial year ended 31^st March, 2025.

1. FINANCIAL STATEMENTS & RESULTS:

a. FINANCIAL RESULTS:

Financial Performance of the Company for the
year ended 31^st March, 2025 as compared to the
previous financial year is summarized below:

b. OPERATIONS OF THE COMPANY:

The Company is be engaged in the business of
manufacturing of finished formulations and
synthetic Active Pharmaceutical Ingredients.
During the year ended 31^st March, 2025,
the Company has recorded income of Rs.
410 crores as against Rs. 386 crores in the
previous year a modest increase of 6%. Profit
after tax stood at Rs. 23.92 crores as against
Rs. 24.74 crores, decrease of 3%.

The Board of Directors at its meeting held
on 18^th November, 2024 inter alia reviewed
and evaluated the re-structuring options for
consolidation of the Business and approved
the termination of Agreement to Sell dated
7^th November, 2022 executed between

the Company and Themis Lifestyle Private
Limited (Now known as Themis Chemicals
Private Limited) a Wholly owned Subsidiary
of the Company for transfer of its Active
Pharmaceutical Ingredients (API) Business on a
going concern basis.

The Board of Directors of the Company, at its
meeting held on 18^th November, 2024, had
also approved the Scheme of Amalgamation
("Scheme") between Gujarat Themis Biosyn
Limited ("GTBL") and the Company and their

respective shareholders under sections 230
to 232 and other applicable provisions of the
Companies Act, 2013, subject to receipt of
necessary regulatory and other approvals.

However, the Board of Directors of GTBL, at its
meeting held on 13^th June, 2025 after evaluating
new developments in the market decided to
focus on its core business of fermentation-
based pharmaceutical intermediates and active
pharmaceutical ingredients and decided to
revisit all its strategic options. Consequently,
the GTBL Board reconsidered its earlier decision
of merger and resolved not to proceed with the
proposed merger. Accordingly, the GTBL Board
has approved the withdrawal of the Scheme as
permitted under clause 21 of the Scheme.

In alignment with this decision, the Board of
Directors of the Company has also resolved to
withdraw the said Scheme of Amalgamation.

Pursuant to this, the Company shall continue
to focus on its core domestic formulations
business with the objective of achieving long
term sustainable growth.

c. REPORT ON PERFORMANCE OF SUBSIDIARIES,
ASSOCIATES AND JOINT VENTURE COMPANIES:

As on 31^st March, 2025, the Company had three
non-material subsidiaries namely, Artemis
Biotech Limited, Themis Chemicals Pvt Ltd. and
Dr. Themis Private Limited.

The Company also had two overseas subsidiaries
incorporated in the United Kingdom, viz; Carpo
Medical Private Limited and Carpo Investments
Private Limited. These two entities have been
struck off from the Companies House in the
United Kingdom (UK) with effect from 1^st April,
2025, in accordance with the applicable laws of
the UK.

The performance and financial position of
each of the subsidiaries and associates for the
year ended 31^st March 2025 in Form AOC-1 is
attached and marked as Annexure I and forms
part of this Report.

d. DIVIDEND:

Your Directors are pleased to recommend
dividend of Re. 0.50 per equity share having
face value of Re. 1 each, on 9,20,40,120 Equity
shares, aggregating to Rs. 4,60,20,060 for the
financial year ended 31^st March, 2025. The

dividend would be subject to the approval of the
members at the forthcoming Annual General
Meeting to be held on Friday, 12^th September,
2025. The said dividend recommendation is
in accordance with the Dividend Distribution
Policy of the Company which is available on
the website of the Company at https://www.
themismedicare.com/uploads/statutory/pdf/
dividend-distribution-policy.pdf

e. TRANSFER TO RESERVES:

Your Company has not transferred any amount
to reserves during the year under review.

f. FIXED DEPOSITS:

During the year, your Company has not accepted
any deposits within the meaning of Section 73
of the Companies Act, 2013 (the "Act") and the
Companies (Acceptance of Deposits) Rules, 2014.

2. DISCLOSURES UNDER SECTION 134(3)(l) OF THE ACT:

Except as disclosed elsewhere in this report, no
material changes and commitments which could
affect the Company's financial position have
occurred between the end of the financial year of
the Company and date of this report.

3. OTHER CONFIRMATIONS:

• The Company has not issued any shares with
differential voting rights / sweat equity shares.

• There has been no change in the nature of
business of the Company as on the date of this
report.

• There was no revision in Company's credit rating
during the year.

• No application was made or any proceedings
were pending under the Insolvency and
Bankruptcy Code, 2016

• Valuation related details for financial year
2024-25 in respect of one-time settlement of
loan from banks or financial institutions are not
applicable

4. DECLARATION OF INDEPENDENCE:

The Independent Directors of the Company have
given the declaration and confirmation to the
Company as required under Section 149(7) of
the Act and Regulation 25(8) of the SEBI Listing
Regulation confirming that they meet the criteria
of independence and that they are not aware of
any circumstances or situation, which exists or may
be reasonably anticipated, that could impair or
impact their ability to discharge their duties with
an objective independent judgement and without
any external influence.

Further, in terms of Section 150 read with
Rule 6 of the Companies (Appointment and
Qualification of Directors) Rules, 2014, as
amended, the Independent Directors of the
Company have included their names in the data
bank of Independent Directors maintained with
the Indian Institute of Corporate Affairs.

5. NOMINATION & REMUNERATION POLICY:

Your Company has constituted Nomination &
Remuneration Committee as provided under
section 178(1) of the Act. The Nomination &
Remuneration Committee considers that the
qualifications, experience and positive attributes
of the Directors on the Board of the Company
are sufficient enough to discharge their duties as
such. The remuneration is being paid to Executive
Chairman and Managing Director is in line with
Schedule V of the Act as also commission and sitting
fees are paid to other Directors for attending Board
and Audit Committee meetings as well as meeting
of Independent Directors.

The Company's Policy on Nomination &
Appointment of Directors, Criteria for Appointment
of Senior Management and Remuneration Policy,
as formulated under Section 178(3) of the Act,
is available on the Company's website at: www.
themismedicare.com

6. PARTICULARS OF LOANS, GUARANTEES,
INVESTMENTS AND SECURITIES:

Details of Loans granted, Guarantees given or
Investments made during the financial year,
covered under the provisions of Section 186 of
the Act are given in the notes to the Financial
Statements.

7. PARTICULARS OF CONTRACTS OR ARRANGEMENT
WITH RELATED PARTIES:

Contracts/arrangements/transactions entered by
the Company during the financial year with related
parties were on an arm's length basis and in the
ordinary course of business.

All related party transactions are placed for the
approval before the Audit Committee and also
before the Board and Shareholders wherever
necessary in compliance with the provisions of the
Act and Listing Regulations. The Audit Committee
at its meeting held on 25^th March, 2025 reviewed
and approved the related party transactions
after considering the minimum information to

be provided as per industry standards for the
financial year 2025-26 and granted prior omnibus
approval for Related Party Transactions as per the
provisions contained in the SEBI Listing Regulations.
A statement giving details of all Related Party
transactions was also placed before the Audit
Committee and Board of Directors for their approval
on quarterly basis.

The policy on materiality of related party
transactions and dealing with related party
transactions as approved by the Board has been
adopted by the Company and uploaded on the
Company's website at the link: https://www.
themismedicare.com/uploads/statutory/pdf/
related-partv-transaction-policv.pdf

8. DISCLOSURE OF INTERNAL FINANCIAL CONTROLS:

The Internal Financial Controls followed by the
Company are adequate and commensurate with
the size and nature of the business and were
operating effectively during the year under review.

Internal Audit function of the Company is carried out
through Independent Chartered Accountants Firms
to test and verify the Company's Internal Control
System. The Company's assets are adequately
safeguarded against significant misuse or loss.
The Company has in place, adequate Internal
Financial Controls with respect to maintenance
of accounting records and financial transactions.
Proper systems have been devised to ensure
compliance with the provisions of all applicable
laws and that such systems were adequate and
operating effectively. The Audit Committee and
the Board reviews the report(s) of the independent
internal auditors at regular intervals along with the
adequacy, effectiveness and observations of the
internal auditors regarding internal control systems
and recommends improvements and remedial
measures wherever necessary.

During the year under review, no material or
serious observations were received from the
Internal Auditors of the Company for inefficiency
or inadequacy of such controls.

9. DISCLOSURE OF SIGNIFICANT & MATERIAL
ORDERS PASSED BY REGULATORS OR COURTS OR
TRIBUNALS:

During the financial year 2024-25 no significant or
material order have been passed by any Regulators
or Courts or Tribunals which can have impact on the
going concern status and its operations in future.

10. DISCLOSURES RELATED TO SHARE CAPITAL AND
EMPLOYEE STOCK OPTIONS:

1. As per provisions of Section 62(1)(b) of the Act
read with Rule 12(9) of the Companies (Share
Capital and Debenture) Rules, 2014 and other
applicable Regulations, details of equity shares
issued if any under Employees Stock Option
Scheme during the financial year under review
is furnished in Annexure II attached herewith
which forms part of this Report. The provisions
of Section 67(3) as well as disclosure under
rule 16(4) of Companies (Share Capital and
Debentures) Rules 2014 are not applicable in
respect of Equity shares allotted against ESOPs
granted to employees.

2. During the year under review, there were no
instances of non-exercising of voting rights
in respect of shares purchased directly by
employees under a scheme and thus no
information is furnished in this regard."

11. BUSINESS RESPONSIBILITY AND SUSTAINABILITY
REPORT (BRSR):

In accordance with Regulation 34(2) of the SEBI
Listing Regulations, the inclusion of Business
Responsibility and Sustainability Report (BRSR) as a
part of the Annual Report is mandated for top 1000
listed entities based on the market capitalization.
BRSR for the financial year 2024-25 has been
prepared in accordance with the format prescribed
by SEBI. The BRSR report forms part of this report.

The BRSR report for the financial year 2024¬
25 has also been hosted on the Company's
website and the same can be accessed at https://
www.themismedicare.com/investor-relations/
annualreport

12. DIRECTORS AND KEY MANAGERIAL PERSONNEL:

In accordance with the provisions of the Act and the
Articles of Association of the Company, Dr. Adam
Demeter (DIN: 10283162), Non-executive Director
of the Company, retires by rotation at the ensuing
Annual General Meeting and being eligible offers
himself for re-appointment. The Board recommends
to the members the re- appointment of Dr. Adam
Demeter (DIN: 10283162) as a Director in the ensuing
Annual General Meeting (AGM) of the Company.

Necessary resolution for the appointment/ re¬
appointment of the Directors is included in the
Notice convening the ensuing AGM and details of
the proposal for appointment/re- appointment
are mentioned in the Explanatory Statement to
the Notice.

Pursuant to Section 161 of the Companies Act,

2013 the Board of Directors of the Company had
appointed Mr. Nikunt Raval (DIN: 10357559) as
an Independent Director of the Company with
effect from 6^th June, 2024 and his appointment
was approved by the members at the 54^th AGM
of the Company held on 22^nd July, 2024.

Mr. Hariharan Subramaniam (DIN: 00162200)
completed his second term as an Independent
Director and retired from the Board at the 54^th
AGM held on 22^nd July, 2024. The Board of Directors
placed on record their appreciation for the valuable
services rendered by Mr. Hariharan Subramaniam
during his tenure as Director of the Company.

Further, the Board, on recommendation of NRC
appointed Mr. Pradeep Chandan as Director-Legal,
Compliance & Company Secretary with effect from
1^st August 2024, in place of Mr. Sangameshwar Iyer,
who superannuated from the services of the
Company. The Board of Directors placed on
record its appreciation to Mr. Iyer for his valuable
contribution during his term as Company Secretary
of the Company.

All the Directors of the Company have confirmed
that they are not disqualified to act as Director in
terms of section 164 of the Act.

13.DISCLOSURES RELATED TO BOARD, COMMITTEES
AND POLICIES:

a. BOARD MEETINGS:

A calendar of regular meetings is prepared and
circulated in advance to the Directors. Pursuant
to the provisions of the Companies Act, 2013
and rules made thereunder, the Board met
Seven times during the year, the details of
which are given in the Corporate Governance
Report which forms part of this Annual Report.
The intervening gap between the meetings was
within the period prescribed under the Act and
the SEBI Listing Regulations.

b. DIRECTORS' RESPONSIBILITY STATEMENT:

In terms of Section 134(5) of the Companies
Act, 2013, in relation to the audited financial
statements of the Company for the year ended
31^st March, 2025, the Board of Directors hereby
confirms that:

i. in the preparation of the annual accounts, the
applicable accounting standards have been
followed and there is no material departure
according to the accounting standards;

ii. such accounting policies have been selected
and applied consistently and the Directors

made judgments and estimates that are
reasonable and prudent so as to give a true
and fair view of the state of affairs of the
Company as at 31^st March, 2025 and of the
profit of the Company for that year;

iii. proper and sufficient care was taken for the
maintenance of adequate accounting records
in accordance with the provisions of this Act
for safeguarding the assets of the Company
and for preventing and detecting fraud and
other irregularities;

iv. the annual accounts of the Company have
been prepared on a going concern basis;

v. internal financial controls have been laid
down to be followed by the Company and
that such internal financial controls are
adequate and were operating effectively;

vi. Proper systems have been devised to
ensure compliance with the provisions of all
applicable laws and that such systems were
adequate and operating effectively.

c. COMMITTEES CONSTITUTED BY THE BOARD OF
DIRECTORS:

In compliance with the requirement of applicable
laws and as part of best governance practices,
the Company has following Committees of the
Board as on 31^st March, 2025:

Committee constituted by the Board

i. Audit Committee;

ii. Stakeholders Relationship Committee;

iii. Nomination & Remuneration Committee;

iv. Corporate Social Responsibility Committee;

v. Risk Management Committee

In addition to the above, a committee of
Independent Directors was constituted for
the purpose of evaluating and approving
the scheme of amalgamation between the
Company and Gujarat Themis Biosyn Limited,
in accordance with the applicable provisions
of the Companies Act, 2013 and SEBI (Listing
Obligations and Disclosure Requirements)
Regulations, 2015. The details with respect
to the aforesaid Committees form part of the
Corporate Governance Report.

d. VIGIL MECHANISM POLICY / WHISTLE BLOWER
POLICY:

Your Company has established a Vigil Mechanism
Policy for Directors, employees and third parties

to report their genuine concerns details of which
have been given in the Corporate Governance
report annexed to this report. This policy is
also available on Company's website and can
be accessed at https://www.themismedicare.
com/uploads/statutory/pdf/vigil-mechanism-
whistle-blower-policy-31.pdf

e. FAMILIARISATION PROGRAMMES FOR
INDEPENDENT DIRECTORS:

The Company conducts familiarization
programmes for Independent Directors and
the details are uploaded on the website of the
Company on the below mentioned link: https://
www.themismedicare.com/uploads/statutory/
pdf/familarization-programme-2024-25.pdf

f. RISK MANAGEMENT POLICY:

Your Company has in place a mechanism to
inform the Board about the risk assessment
and minimization procedure and undertakes
periodical review of the same to ensure that
the risks are identified and controlled by
means of a properly defined framework. As per
Regulation 21 of the SEBI Listing Regulations,
Risk Management Committee of the Company
has been constituted by the Board on 11^th
February, 2022.

The composition of the Risk Management
Committee of the Company is as under:

g. CORPORATE SOCIAL RESPONSIBILITY POLICY:

As per the provisions of Section 135 of the
Act read with Companies (Corporate Social
Responsibility Policy) Rules, 2014, the Board
of Directors has constituted a Corporate Social
Responsibility (CSR) Committee.

Annual Report on CSR activities as required
under the Companies (Corporate Social
Responsibility Policy) Rules, 2014 has been
appended as Annexure - III and forms an
integral part of this Report.

The Company has formulated policy for CSR
activities and is placed on the website of the
Company at https://www.themismedicare.
com/uploads/statutorv/pdf/csr-policv-with-
amendments.pdf

During the year under the review three CSR

committee meetings were held.

h. ANNUAL PERFORMANCE EVALUATION:

Pursuant to the provisions of the Companies
Act 2013 and Regulation 17 of the Listing
Regulations and in accordance with the
parameters suggested by the Nomination &
Remuneration policy, the Board of Directors
carried out an annual evaluation of its own
performance, Board, Committees and Individual
Directors pursuant to the provisions of the Act
and the Corporate Governance requirements
as prescribed by the SEBI Listing Regulations.
Feedback was sought by way of a structured
questionnaire covering various aspects of the
Board's functioning, such as adequacy of the
composition of the Board and its Committees,
Board culture, execution and performance of
specific duties, obligations and governance.

In a separate meeting of Independent Directors
held on 25^th March 2025, performance of
Non-Independent Directors, performance of
the Board as a whole and performance of the
Chairman was evaluated, taking into account
the views of other Non-Executive Directors.
Performance evaluation of Independent
Directors was done by the entire Board.

A brief summary of outcome of the Board
evaluation along with the action plan for
implementing the recommendations made by
the Directors was presented to the Board.

i. DISCLOSURE UNDER SECTION 197(12) OF
THE ACT AND OTHER DISCLOSURES AS PER
RULE 5 OF COMPANIES (APPOINTMENT &
REMUNERATION) RULES, 2014:

The information required under Section 197
of the Act read with Rule 5 of the Companies
(Appointment and Remuneration of Managerial
Personnel) Rules 2014 is furnished in
AnnexureIV

The statement containing names of employees
in terms of remuneration drawn and the
particulars of employees as required under
Section 197(12) of the Act read with Rule 5(2)
and 5(3) of the Companies (Appointment and
Remuneration of Managerial Personnel) Rules
2014 is provided in a separate annexure forming
part of this report. Further, the report and
the accounts are being sent to the Members
excluding the aforesaid annexure. In terms of
Section 136 of the Act and the said annexure
is open for inspection. Any Member interested

in obtaining a copy of the said statement may
write to the Company Secretary at pradeep.
chandan@themismedicare.com

j. PAYMENT OF REMUNERATION / COMMISSION
TO DIRECTORS FROM HOLDING OR SUBSIDIARY
COMPANIES:

None of the Directors or managerial personnel
of the Company is in receipt of remuneration/
commission from any Subsidiaries of the
Company.

14.AUDITORS:

a. APPOINTMENT OF STATUTORY AUDITORS:

M/s Krishaan & Co., Chartered Accountants
(ICAI COP no. 208431) were appointed as
Statutory Auditors of the Company at the 52^nd
Annual General Meeting of the Company held
on 19^th September 2022 to hold office from the
conclusion of the said meeting till the conclusion
of the 57^th AGM to be held in financial year 2027

b. MAINTENANCE OF COST RECORDS:

Maintenance of cost records is required as
specified by the Central Government under
sub-section (1) of section 148 of the Act and
accordingly such accounts and records are
made and maintained.

c. COST AUDITORS:

Pursuant to the provisions of Section 148
of the Act read with the Companies (Cost
Records and Audit) Rules, 2014, the Board of
Directors on recommendation of the Audit
Committee, appointed M/s. B. J. D. Nanabhoy
& Co., Cost Accountants as the Cost Auditors
of the Company for the financial year 2025-26
for conducting the audit of the cost accounting
records maintained by the Company in respect
of API and formulation activities of the Company.

Pursuant to Section 148 of the Act read with the
Companies (Audit and Auditors) Rules, 2014,
appropriate resolution seeking ratification to
the payment of remuneration to the said Cost
Auditors is appearing in the Notice convening
the 55^th AGM of the Company.

d. SECRETARIAL AUDITORS:

Pursuant to the provisions of section 204 of
the Companies Act, 2013 and the Companies
(Appointment and Remuneration of Managerial
Personnel) Rules, 2014, the Company had
appointed M/s. SAV & Associates LLP, (COP No.
825) Practicing Company Secretaries, Mumbai,

to conduct Secretarial Audit for the financial
year 2024-25.

Secretarial Audit Report issued by M/s. SAV &
Associates LLP, Practicing Company Secretaries,
in Form MR-3 for the financial year 2024-25
forms part of Annual report. The Secretarial
Audit Report is annexed to this report as
Annexure- V.

In accordance with the SEBI (Listing Obligations
and Disclosure Requirements) (Third Amendment)
Regulations, 2024 dated 12^th December, 2024,
the Secretarial Auditors shall now be appointed
by the Members of the Company, on the
recommendation of the Board of Directors, for a
period of five (5) consecutive years.

Based on the recommendation of the Audit
Committee, the Board, at its Meeting held
on 20^th May, 2025, subject to the approval
of the Members of the Company, approved
appointment of M/s. SAV & Associates LLP,
Company Secretaries as the Secretarial
Auditors of the Company, for a term of 5 (five)
consecutive financial years, to hold office from
Financial Year 2025-26.

e. Qualification/ Reservation in the Statutory
Audit/ Secretarial Audit reports:

There are no qualification, reservation or
adverse remarks or disclaimer made by
Statutory Auditor or Secretarial Auditor in their
respective reports for the financial year ended
31^st March, 2025.

f. Compliance with Secretarial Standards:

Your Company has duly complied with the
applicable Secretarial Standard, (SS) issued
by the Institute of Company Secretaries of
India relating to meetings of the Board and its
committee (SS1) and General Meeting (SS2)
respectively during the year under review.

15.OTHER DISCLOSURES:

Other disclosures as per provisions of Section 134
of the Act read with Companies (Accounts) Rules,
2014 are furnished as under:

a. ANNUAL RETURN:

Pursuant to Section 92(3) read with Section
134(3)(a) of the Act, the Annual Return as on
31^st March, 2025 is available on the Company's
website on https://www.themismedicare.com;

b. CONSERVATION OF ENERGY, TECHNOLOGY
ABSORPTION AND FOREIGN EXCHANGE
EARNINGS AND OUTGO:

The particulars as required under the provisions
of Section 134(3) (m) of the Companies Act, 2013
read with Rule 8 of the Companies (Accounts)
Rules, 2014 in respect of conservation of
energy, technology absorption, foreign
exchange earnings and outgo etc. are furnished
in Annexure VI which forms part of this Report.

c. MANAGEMENT DISCUSSION AND ANALYSIS
REPORT:

In terms of the SEBI Listing Regulations, the
Management Discussion and Analysis report is
annexed to this Annual report.

d. CORPORATE GOVERNANCE:

A separate report on Corporate Governance
along with a Certificate of Practicing Company
Secretary regarding compliance of the conditions
of Corporate Governance as stipulated in
regulation 17 to 27 and clauses (b) to (i) of sub¬
regulation (2) of regulation 46 of the SEBI Listing
Regulations with the Stock Exchanges forms
part of this Annual report.

e. REPORTING OF FRAUD BY AUDITORS

During the year under review, the Statutory
Auditors, Cost Auditors and Secretarial Auditors
have not reported any instances of frauds
committed in your Company by its Officers
or Employees to the Audit Committee under
section 143(12) of the Act.

f. PREVENTION OF SEXUAL HARASSMENT AT THE
WORKPLACE:

Your Company gives prime importance to the
dignity and respect of its employees irrespective
of their gender or hierarchy and expects
responsible conduct and behaviors on the part
of employees at all level.

Your Company has zero tolerance for sexual
harassment at the workplace and has adopted a
Policy on prevention, prohibition and redressal
of sexual harassment at the workplace in line
with the provisions of the Sexual Harassment of
Women at Workplace (Prevention, Prohibition
and Redressal) Act, 2013 and the Rules framed
thereunder for prevention and redressal
of Complaints of Sexual Harassment at the
workplace. The Company has constituted an
Internal Committee (IC) and name of the
members of the IC are displayed on the notice
board of each office and manufacturing units of
the Company.

There was no Complaint of sexual harassment
received during the financial year 2024-25

g. DETAILS OF SIGNIFICANT CHANGES IN KEY
FINANCIAL RATIOS (I.E. CHANGE OF 25% OR
MORE AS COMPARED TO THE IMMEDIATELY
PREVIOUS FINANCIAL YEAR):

h. DETAILS OF ANY CHANGE IN RETURN
ON NET WORTH AS COMPARED TO THE
IMMEDIATELY PREVIOUS FINANCIAL YEAR
ALONG WITH A DETAILED EXPLANATION
THEREOF.:

i. EMPLOYEES RELATIONS:

Your Board of Directors place on record their
sincere appreciation of the contributions made
by the employees at all level to the growth of
the Company.

Industrial relations at all our manufacturing
sites remained cordial.

ACKNOWLEDGEMENTS AND APPRECIATION:

Your Board of Directors take this opportunity
to thank all stakeholder including customers,
shareholders, suppliers, bankers, business partners/
associates, collaborators, financial institutions and
Central and State Governments for their consistent
support and encouragement to the Company. Your
Directors also thank the Members and Investors for
their confidence in the Company.

For and on behalf of the Board of Directors

Sd/- Sd/-

Dr. Dinesh S. Patel Dr. Sachin D. Patel

Chairman Managing Director & CEO

DIN:00033273 DIN:00033353

Place: Mumbai
Dated: 20^th May, 2025